MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), ...

Hexavalent, six-in-one vaccine can reduce spread of the disease and cut costs ANALYSIS | ESTHER NAKKAZI | Pertussis, or ...

New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results ...

Fourteen percent of the world's people -- more than 800 million -- now have diabetes, a doubling of the global rate for the ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...

As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with ...

Hørsholm, Denmark, 14 November 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its third quarter and year-to-date financial results for 2024. The report is available as an attachme ...

With the Covid-19 epidemic in Denmark under control and other vaccines available, it was decided to discontinue the use of the AZ product. Argentina has deepened Wednesday its restrictive measures ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...